inclusion criteria: * patients 18 years of age or older who have given their written consent to participate in the study. * hospitalized and treated with oxygen for a maximum of 48 hours. * verified covid-19: positive sample for sars-cov2 rna or a positive sars-cov2 antigen test from the upper respiratory tract * receives oxygen treatment. * negative pregnancy test (women of childbearing potential) * willing to exercise contraception categorized as "very effective" according to the clinical trial facilitation group during ongoing study treatment + 7 days (appendix 2). (female research participant of childbearing potential)

inclusion criteria: * patients 18 years of age or older who have given their written consent to participate in the study. * hospitalized and treated with oxygen for a maximum of 48 hours. * verified covid-19: positive sample for sars-cov2 rna or a positive sars-cov2 antigen test from the upper respiratory tract * receives oxygen treatment. * negative pregnancy test (women of childbearing potential) * willing to exercise contraception categorized as "very effective" according to the clinical trial facilitation group during ongoing study treatment + 7 days (appendix 2). (female research participant of childbearing potential)

inclusion criteria: patients 18 years of age or older who have given their written consent to participate in the study. hospitalized and treated with oxygen for a maximum of 48 hours. verified covid-19: positive sample for sars-cov2 rna or a positive sars-cov2 antigen test from the upper respiratory tract receives oxygen treatment. negative pregnancy test (women of childbearing potential) willing to exercise contraception categorized as "very effective" according to the clinical trial facilitation group during ongoing study treatment + 7 days (appendix 2). (female research participant of childbearing potential)

inclusion criteria: patients 18 years of age or older who have given their written consent to participate in the study. hospitalized and treated with oxygen for a maximum of 48 hours. verified covid-19: positive sample for sars-cov2 rna or a positive sars-cov2 antigen test from the upper respiratory tract receives oxygen treatment. negative pregnancy test (women of childbearing potential) willing to exercise contraception categorized as "very effective" according to the clinical trial facilitation group during ongoing study treatment + 7 days (appendix 2). (female research participant of childbearing potential)

inclusion criteria: patients 18 or older who are willing and able to provide written informed consent. laboratory-confirmed (pcr-positive) sars-cov-2 infection. receiving supplemental oxygen therapy with start <48 hours before inclusion. negative pregnancy test (women in fertile age). agreeing to take highly effective contraceptive measures according to clinical trial facilitation group criteria during the duration of treatment plus 7 days (women in fertile age).

inclusion criteria: patients 18 or older who are willing and able to provide written informed consent. laboratory-confirmed (pcr-positive) sars-cov-2 infection. receiving supplemental oxygen therapy with start <48 hours before inclusion. negative pregnancy test (women in fertile age). agreeing to take highly effective contraceptive measures according to clinical trial facilitation group criteria during the duration of treatment plus 7 days (women in fertile age).

inclusion criteria: 1. patients 18 or older who are willing and able to provide written informed consent. 2. laboratory-confirmed (pcr-positive) sars-cov-2 infection. 3. receiving supplemental oxygen therapy with start <48 hours before inclusion. 4. negative pregnancy test (women in fertile age). 5. agreeing to take highly effective contraceptive measures according to clinical trial facilitation group criteria during the duration of treatment plus 7 days (women in fertile age).

inclusion criteria: 1. patients 18 or older who are willing and able to provide written informed consent. 2. laboratory-confirmed (pcr-positive) sars-cov-2 infection. 3. receiving supplemental oxygen therapy with start <48 hours before inclusion. 4. negative pregnancy test (women in fertile age). 5. agreeing to take highly effective contraceptive measures according to clinical trial facilitation group criteria during the duration of treatment plus 7 days (women in fertile age).